KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $242.5 million.

  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity rose 73.96% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $789.2 million, marking a year-over-year increase of 54.27%. This contributed to the annual value of $164.0 million for FY2024, which is 39.88% up from last year.
  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity amounted to $242.5 million in Q3 2025, which was up 17.32% from $206.7 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $242.5 million during Q3 2025, with a 5-year trough of $115.3 million in Q3 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $128.4 million (2024), whereas its average is $150.6 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Liabilities and Shareholders Equity crashed by 38.02% in 2022, and later soared by 73.96% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $167.3 million in 2021, then fell by 19.75% to $134.3 million in 2022, then dropped by 12.70% to $117.2 million in 2023, then spiked by 39.88% to $164.0 million in 2024, then spiked by 73.96% to $242.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $242.5 million for Q3 2025, versus $206.7 million for Q2 2025 and $176.0 million for Q1 2025.